by VX Pharma | Sep 26, 2013 | Total Biopharma
Eli Lilly has announced the results of two separate Phase III trials with its cancer mAb ramucirumab – and there’s good news and bad news. The drug failed to reach its primary endpoint in the breast cancer indication, yet successfully met its goal in a separate...
by VX Pharma | Sep 24, 2013 | Total Biopharma
Generic drug use in the US jumped up 8% in 2012, keeping the growth rate of health care spending stable for the third straight year. This is according to a new report from the Health Care Cost Institute, which examined claims made by Americans aged 65 and under with...
by VX Pharma | Sep 10, 2013 | Total Biopharma
In a letter to UK newspaper The Times, the chief executive of the National Institute for Health and Care Excellence (NICE) has challenged the real costs of pharmaceutical research and development. Sir Andrew Dillon, who has headed up the UK health technology...
